Although the acute form of human melioidosis with its attendant high mortality has long been a distinct therapeutic problem (1, 8) , additional concern has been expressed recently for improved therapy of the persistent, inapparent, and potentially recrudescent forms of infection by Pseudomonas pseudomallei (4, 7, 14, 16) . In particular, there continues to be a need for therapeutic agents and regimens which offer hope for an eradicative action in these chronic forms of melioidosis.
The present studies were undertaken because a preliminary report of mouse tests and tests in vitro on a new antibiotic, rifampin, suggested outstanding effectiveness (9). Also, since tetracycline has been indicated for clinical use as a preferred drug (15), it was included along with several related derivatives for tests of comparative activity. Moreover, the attempt to correlate susceptibility data derived in vitro with controlled experimental infection test results was a desirable objective in these studies.
This report is part of a larger program which involved many strains, many antibacterials, and the development of reproducible acute and chronic infections in mice. These studies, which will be reported elsewhere, revealed that the use of acute infection models (with or without mucin) for drug testing not only tended to provide exaggerated drug effects but also failed to permit a proper examination of eradicative effects, the development of resistance, and the evaluation of drug treatment regimens and combinations. In these present tests, therefore, persistent types of nonadjuvanted experimental infections were used, 13 and, to add to clinical relevance, treatment was withheld to permit firm establishment of the bacterial infection. In addition, treatment was by drug-diet, to provide some constancy of dosage without excessive manipulation of the infected mice.
MATERIALS AND METHODS
Tests in vitro were performed with 64 strains of P. pseudomallei, including a number of recent clinical isolates as well as cultures obtained from human and animal sources dating as far back as 1946 (8). All strains were of confirmed identity through appropriate cultural, morphological, and biochemical tests.
Susceptibility tests in vitro. Using tryptic soy broth, minimal inhibitory concentrations (MIC) determinations were carried out in tube-dilution tests based upon inocula of approximately 104 colony-forming units (CFU) per tube, 5 ml of broth per tube, 37 C incubation temperature, and end point readings made at 24 hr. Rifampin was lot D1281 (Pittman-Moore); doxycycline HCl, lot 85525-58002 (Pfizer); methacycline HCI, lot 93868-56010 (Pfizer); minocycline HC1, lot 7412B-56 (Lederle); and tetracycline HCl, lot 174-009 (Lederle).
As a check on the potency of lot D1281 rifampin used in these tests, MIC determinations were carried out against a number of bacterial species other than P. pseudomallei. The results of such tests indicated that this rifampin preparation possessed expected antibacterial potency, and details are accordingly not given here.
Mouse chemotherapy tests. Female CD-1 (Charles River) mice, 18 to 22 g, were used throughout. Mice were housed in groups of 10 in glass or plastic cages and were sustained on a water and ground pellet diet. isolated from a patient who had acquired melioidosis in Viet Nam. The MIC's for relevant antibiotics for these two mouse-infecting strains, PM-22 and PM-1, respectively, were (in pg/ml): rifampin, 12.5 and 25.0; tetracycline, 1.6 and 3.1; minocycline, 1.6 and 1.6; methacycline, 1.6 and 1.6; doxycycline, 0.8 and 0.8. The choice of these two strains came from many previous tests which indicated that highly reproducible, slowly progressive, generally fatal infections in mice could be accomplished for either strain without the concomitant use of mucin. Also, strain PM-22 consistently induced a subacute infection, with a median death time in untreated mice of about 13 days after intraperitoneal challenge with approximately 104 CFU per mouse. At a similar intraperitoneal challenge level, strain PM-1 provided a more prolonged type of infection, with a median death time of about 24 days. With either strain, preliminary studies showed that these challenges had produced early localized infections after 3 days, principally in the spleen.
RESULTS
Results of tests in vitro with up to 64 strains of P. pseudomallei are given in Table 1 Tables 2-4, with Table 2 reporting on tests with strain PM-22, Table 3 for strain PM-1, and Table  4 a Median survival time.
In contrast, a different picture developed from the mouse therapy tests. In terms of overall efficacy, rifampin appeared superior to tetracycline, methacycine, and doxycycine; however, minocycine was generally somewhat more effective. More specifically, in the subacute infection by strain PM-22, rifampin and minocycine appeared to be of moderate and comparable activity; tetracycline performed poorly (survival and bacterial eradication percentages equal to or less
